<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549429</url>
  </required_header>
  <id_info>
    <org_study_id>12884</org_study_id>
    <nct_id>NCT03549429</nct_id>
  </id_info>
  <brief_title>Tegaderm vs. EyeGard for Eye Protection</brief_title>
  <official_title>A Randomized Control Trial of Tegaderm vs. EyeGard for Eye Protection During General Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tufts Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares TegadermTM and EyeGard® in general anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protective eye tape is used during anesthesia in order to prevent corneal abrasion and other
      eye injuries. However, there is no single accepted practice of how to protect the eyes during
      anesthesia, and a variety of different tapes and techniques have been adopted in different
      institutions. In this study, investigators will compare two tapes, TegadermTM and EyeGard® to
      determine if one is less likely to cause eyelid irritation in an effort to improve care for
      future patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">July 20, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Every patient will have each tape on each eye -EyeGard® on one eye and the TegadermTM on the other eye according to the randomization schema.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants With Eyelid Erythema</measure>
    <time_frame>Standardized photos will be taken within 5 minutes of removing tape after surgery (surgery of any duration)</time_frame>
    <description>The amount of erythema caused upon removal of the tape is the primary outcome of interest. Investigators will use the following 0-3 tape-associated skin index grading scale to grade eyelid erythema:
0- no erythema
mild erythema
moderate erythema
severe erythema The primary outcome will then be converted to a binary scale (0= no erythema, 1= erythema) for the purposes of analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>post-operation</time_frame>
    <description>Patient Satisfaction will be based on one question and graded on a Likert Scale from 1-5. A score of 5 is considered better (higher satisfaction), while a 1 is considered lower. There are no subscales.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Corneal Abrasions</measure>
    <time_frame>post-operation</time_frame>
    <description>Corneal abrasion is assessed in the recovery room</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Erythema</condition>
  <arm_group>
    <arm_group_label>TegadermTM on R eye, EyeGard® on L eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get TegadermTM on Right eye, EyeGard® on Left eye</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TegadermTM on L eye, EyeGard® on R eye</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will get TegadermTM on Left eye, EyeGard® on Right eye</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medical tapes: TegadermTM and EyeGard®</intervention_name>
    <description>TegadermTM and EyeGard® will be placed over patients' eyes during surgery with general anesthesia.</description>
    <arm_group_label>TegadermTM on L eye, EyeGard® on R eye</arm_group_label>
    <arm_group_label>TegadermTM on R eye, EyeGard® on L eye</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18

          -  Surgeries scheduled for anesthesia of any duration

        Exclusion Criteria:

          -  Any patient that does not consent

          -  Any patient who has:

          -  Pre-existing eyelid erythema or other eyelid trauma

          -  Eyelid piercings

          -  Any surgery on the head, brain, neck, teeth, mouth, eyes or face

          -  Surgery in the prone position

          -  Patients &lt;18 years old
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Drzymalski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts Medical Center Dept. of Anesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2018</study_first_posted>
  <results_first_submitted>June 12, 2019</results_first_submitted>
  <results_first_submitted_qc>August 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erythema</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT03549429/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 159 patients were enrolled (consented) but not randomized. The reasons for not randomizing include:
Research assistant unavailable (n=6)
Anesthetic plan change (n=4)
Surgical plan change (n=4)
Tape sensitivity (n=1)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TegadermTM on R Eye, EyeGard® on L Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
        <group group_id="P2">
          <title>TegadermTM on L Eye, EyeGard® on R Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Those who were eligible were analyzed</population>
      <group_list>
        <group group_id="B1">
          <title>TegadermTM on R Eye, EyeGard® on L Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
        <group group_id="B2">
          <title>TegadermTM on L Eye, EyeGard® on R Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Participants With Eyelid Erythema</title>
        <description>The amount of erythema caused upon removal of the tape is the primary outcome of interest. Investigators will use the following 0-3 tape-associated skin index grading scale to grade eyelid erythema:
0- no erythema
mild erythema
moderate erythema
severe erythema The primary outcome will then be converted to a binary scale (0= no erythema, 1= erythema) for the purposes of analysis.</description>
        <time_frame>Standardized photos will be taken within 5 minutes of removing tape after surgery (surgery of any duration)</time_frame>
        <population>Inclusion Criteria: Age ≥ 18, surgeries scheduled for anesthesia of any duration.
Exclusion Criteria: Any patient that does not consent, any patient who has pre-existing eyelid erythema or other eyelid trauma/piercings, any surgery on the head, brain, neck, teeth, mouth, eyes or face, surgery in the prone position, patients &lt;18 years old</population>
        <group_list>
          <group group_id="O1">
            <title>Erythema With TegadermTM Only</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
          <group group_id="O2">
            <title>Erythema With EyeGard® Only</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Eyelid Erythema</title>
          <description>The amount of erythema caused upon removal of the tape is the primary outcome of interest. Investigators will use the following 0-3 tape-associated skin index grading scale to grade eyelid erythema:
0- no erythema
mild erythema
moderate erythema
severe erythema The primary outcome will then be converted to a binary scale (0= no erythema, 1= erythema) for the purposes of analysis.</description>
          <population>Inclusion Criteria: Age ≥ 18, surgeries scheduled for anesthesia of any duration.
Exclusion Criteria: Any patient that does not consent, any patient who has pre-existing eyelid erythema or other eyelid trauma/piercings, any surgery on the head, brain, neck, teeth, mouth, eyes or face, surgery in the prone position, patients &lt;18 years old</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We compared the proportion of patients who had postoperative eyelid erythema with Tegaderm™ to those who had postop eyelid erythema with EyeGard®.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>McNemar</method>
            <param_type>Percent difference</param_type>
            <param_value>8.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.5</ci_lower_limit>
            <ci_upper_limit>14.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction</title>
        <description>Patient Satisfaction will be based on one question and graded on a Likert Scale from 1-5. A score of 5 is considered better (higher satisfaction), while a 1 is considered lower. There are no subscales.</description>
        <time_frame>post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TegadermTM</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
          <group group_id="O2">
            <title>EyeGard®</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Satisfaction</title>
          <description>Patient Satisfaction will be based on one question and graded on a Likert Scale from 1-5. A score of 5 is considered better (higher satisfaction), while a 1 is considered lower. There are no subscales.</description>
          <units>Units on a scale of 1-5</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" spread="0.42"/>
                    <measurement group_id="O2" value="4.91" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>paired</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.03</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Corneal Abrasions</title>
        <description>Corneal abrasion is assessed in the recovery room</description>
        <time_frame>post-operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TegadermTM</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
          <group group_id="O2">
            <title>EyeGard®</title>
            <description>TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia. Half of the participants (n=76) will receive TegadermTM over their right eyelid and EyeGard over the left eyelid. The other half of the participants (n=75) will receive TegadermTM over their left eyelid and EyeGard over the right eyelid.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Corneal Abrasions</title>
          <description>Corneal abrasion is assessed in the recovery room</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For the length of participation in the study; approx. 3-10 hours</time_frame>
      <desc>This study does not pose any additional safety risks beyond those associated with the application of protective tape over the patient’s eyelids that occurs during standard surgical procedures. These risks include injury to the eyelid such as mild to severe erythema, edema, and abrasion.</desc>
      <group_list>
        <group group_id="E1">
          <title>TegadermTM on R Eye, EyeGard® on L Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
        <group group_id="E2">
          <title>TegadermTM on L Eye, EyeGard® on R Eye</title>
          <description>Medical tapes: TegadermTM and EyeGard®: TegadermTM and EyeGard® will be placed over patients’ eyes during surgery with general anesthesia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dan Drzymalski</name_or_title>
      <organization>Tufts Medical Center</organization>
      <phone>‪617-913-8168</phone>
      <email>ddrzymalski@tuftsmedicalcenter.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

